Drug General Information (ID: DDIFUI7BDZ)
Drug Name			Anti-inhibitor coagulant complex		Drug Info		Emicizumab		Drug Info
Drug Type		Protein/peptide				Monoclonal antibody
Therapeutic Class		Coagulation Modifiers				Coagulation Modifiers

Mechanism of Anti-inhibitor coagulant complex-Emicizumab Interaction (Severity Level: Major)
Additive thrombogenic effects Click to Show/Hide Mechanism Graph
Drug Name		Anti-inhibitor coagulant complex				Emicizumab
Mechanism		Thrombogenic effects				Thrombogenic effects
Key Mechanism Factor 1
		Factor Name		Thrombogenic effects
		Factor Description		Drug-induced thrombosis disrupts the balance between thrombogenic factors and protective mechanisms and tends to produce thrombosis. Drug-induced thrombosis usually causes venous thrombotic events, and arterial thrombotic events are also noted as a result of drug administration
Mechanism Description		Additive thrombogenic effects by the combination of Anti-inhibitor coagulant complex and Emicizumab

Recommended Action
Management		Close monitoring is recommended when activated prothrombin complex concentrate must be used during emicizumab prophylaxis. Immediately discontinue aPCC and suspend dosing of emicizumab if clinical symptoms, imaging, and/or laboratory findings consistent with TMA or thromboembolism occur, and manage as clinically indicated. Consider the benefits and risks of resuming emicizumab prophylaxis following complete resolution of TMA or thromboembolism on a case-by-case basis.

References
1	Product Information. Hemlibra (emicizumab). Genentech, South San Francisco, CA.